It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
The Lightning Round is extended in this CNBC.com exclusive feature.
Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners and Philip Tasho, CEO and CIO at Tamro Capital shared their insights.
Stocks trading under $5 typically have no analysts' coverage. However, a select few boast of favorable coverage from analysts. The following 10 U.S. stocks trade at less than $5 and have garnered the most "buy" ratings from analysts. ...A report from TheStreet.
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea by attending a biotech or healthcare investment conference. Many firms put on the events for their clients and they often invite reporters to hang out. ... The PR guy told me a couple of sessions during the day would be "closed" to me. It wasn't clear what the closed sessions were all about, and so my curiousity was piqued...
Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.